Page last updated: 2024-08-23

idarubicin and cytosine

idarubicin has been researched along with cytosine in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Giles, FJ	1
Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA	1
Berry, DA; Cortes, JE; Estey, EH; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Thomas, DA; Verstovsek, S; Wathen, JK; Xiao, LC	1

Reviews

1 review(s) available for idarubicin and cytosine

Article	Year
Troxacitabine-based therapy of refractory leukemia. Expert review of anticancer therapy, 2002, Volume: 2, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Cytosine; Dioxolanes; Humans; Idarubicin; Leukemia; Remission Induction; Topotecan	2002

Trials

2 trial(s) available for idarubicin and cytosine

Article	Year
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome	2003
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-01, Volume: 21, Issue:9 Topics: Acute Disease; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytosine; Dioxolanes; Female; Humans; Idarubicin; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival; Treatment Outcome	2003

Article

Year

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome

2003

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-01, Volume: 21, Issue:9

Topics: Acute Disease; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytosine; Dioxolanes; Female; Humans; Idarubicin; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival; Treatment Outcome

2003